Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial ...

Nanoparticles are designed to enhance activity of T-cells, the white blood cells used by the immune system to fight disease, ...

University of Queensland researchers are designing nanotechnology they believe could improve how we treat the most aggressive form of breast cancer.

A team of researchers from the Hospital del Mar Research Institute, the Universitat Autònoma de Barcelona and the Pompeu ...

Vicero, Inc., a preclinical-stage biopharmaceutical company developing next-generation VINCOBODIES for immune-mediated diseases, today announced the appointment of two distinguished oncologists and ...

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses SAFEbody technology utilized to create masked ...

An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...

University of Queensland researchers are designing nanotechnology they believe could improve how we treat the most aggressive ...

Pathios Therapeutics Limited ("Pathios"), a biotech company focused on the development of first-in-class therapies for cancer, today announced the appointment of Sumeet Ambarkhane, M.D., as Chief ...

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer. Initiation of trial sites underway for ground ...

Researchers in Australia are developing next-generation nanoparticles to supercharge current treatments for triple-negative ...